耐药基因P170,GSTpi在肺癌中的表达及其临床意义

目的为探讨肺癌对耐药基因P170,GSTpi的表达情况和临床意义。方法应用S-P微波免疫组化法对43例肺癌进行了检测。结果显示肺癌中P170GSTpi总阳性表达率为51．1％及55．8％,其中SCLC（18．2％与27．3％）明显低于NSCDe（63．5％与65．85％）,在NSCLC中癌瘤分化程度与P170,GSTpi的表达有正相关倾向,曾做化疗的肺癌中耐药基因的阳性率增高。结论研究结果说明,检测癌组织中P170,GSTpi对肺癌化疗有重要的指导意义,同时应强调肺癌的化疗应特别注意规范化。

Expression of P170,GSTpi in lung carcinomas and their clinical significance

Objective To approch drug-resistant gene P170, GSTpi expression and their clinical significance in lung carcinomas. Methods 43 cases of lung carinoma were examined with S-P immunohistochemistry . Results The total positive expression rates of P170, GSTpi in lung careinoma were 51. 1% and 55.8%, of which small cell lung carcinoma (SCLC, 18.2% and 27.3%) were notably lower than non small cell lung carcinoma (NSCLC, 63.5% and 65.85%). There was a tendency of positive correlation between differentiated degree of carcinoma and the expression of P170, GSTpi in NSCLC. The positive rate of resistant gene performed in lung carcinoma with chemotherapy was increased . Conclusions To detect P170, GSTpi in carcinomous tissue is important and has instructive significance for chemotherapy of lung careinoma. The standardization of the therapy must be paid attention to.